“ZUF has participated in trials for Cipla Pharmaceutical and Boehringer for Pirfenidone and Nintedanib, two of the drugs that were referred to in the article.”
Open Access 01.12.2021 | Correction
Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
Erschienen in: BMC Medicine | Ausgabe 1/2021